Brian M. Wolpin, MD, MPH, discusses phase 1/2 data showing high activity with daraxonrasib in first-line metastatic pancreatic ductal adenocarcinoma.
Brian M. Wolpin, MD, MPH
Advertisement
Articles by Brian M. Wolpin, MD, MPH
Dr. Brian Wolpin discusses updated safety and efficacy results from the Phase 1 study of RMC-6236, a RAS(ON) multi-selective inhibitor, highlighting its promising activity, manageable safety profile, and encouraging survival outcomes in patients with RAS mutant pancreatic ductal adenocarcinoma.
Brian M. Wolpin, MD, MPH, discusses the GI subgroup findings of the Circulating Cell-Free Genome Atlas study.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Pumitamig Plus Chemo Demonstrates Encouraging Efficacy in Frontline NSCLC
2
Iza-Bren Improves Survival in Unresectable, Locally Advanced or Metastatic TNBC
3
Mocertatug Rezetecan Drives Rapid, Deep Responses in Platinum-Resistant Ovarian and Recurrent/Advanced Endometrial Cancer
4
Zongertinib, Sevabertinib Reshape Treatment Landscape for Patients With HER2-Mutated NSCLC
5